Biotech upstart gets $50M to test new virus-based therapies against solid tumors
The team at OncoMyx is trying to leverage one therapeutic to treat several forms of cancer, using the Myxoma virus. Wednesday, it announced the closing of a $50 million Series B financing to take it a step closer to that goal.
The round was co-led by Lumira Ventures and B Capital Group with participation from LYZZ Capital and its Series A investors Boehringer Ingelheim Venture Fund, Delos Capital, Xeraya Capital, Korea Investment Partners, City Hill Ventures, and Madison Partners. Beni Rovinski, the managing director at Lumira Ventures, and Widya Mulyasasmita, the senior principal of healthcare at B Capital Group, will join the companies board of directors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.